Rybelsus Tracker App
Track Oral Semaglutide Doses, HbA1c, and Side Effects in Shotlee
Rybelsus (oral semaglutide) is the first GLP-1 receptor agonist available as a daily tablet for type 2 diabetes. PIONEER-1 demonstrated up to -1.9% HbA1c reduction at the 14 mg dose. Because Rybelsus requires a strict administration routine — empty stomach, no more than 120 mL water, 30-minute wait — consistent daily tracking in Shotlee helps you stay adherent and measure your results over time.
25,000+
GLP-1 Users Tracking
4.8★
App Rating
Free
Always Free
What Is Rybelsus (Oral Semaglutide)?
Rybelsus is the brand name for oral semaglutide, a GLP-1 receptor agonist approved by the FDA in September 2019 for adults with type 2 diabetes. It contains the same active molecule as Ozempic (injectable semaglutide), but is formulated as a once-daily tablet using a proprietary SNAC (salcaprozate sodium) absorption enhancer.
The SNAC excipient temporarily raises local gastric pH and protects semaglutide from enzymatic degradation, enabling approximately 1% oral bioavailability — sufficient for therapeutic effect despite the limitations of oral peptide delivery. This makes Rybelsus the first GLP-1 agonist that does not require injection, an important option for patients with needle aversion or injection barriers.
Administration Is Critical
Rybelsus must be taken on an empty stomach with no more than 120 mL (4 oz) of water. Wait at least 30 minutes before eating, drinking other fluids, or taking other medications. Deviating from this routine significantly reduces absorption.
Rybelsus Dose Escalation Schedule
3 mg
Month 1 (Days 1–30)
Starting dose to improve GI tolerability. Not expected to provide full glycaemic efficacy — this is a tolerance-building step.
7 mg
Month 2+ (Day 31+)
Therapeutic maintenance dose. PIONEER-1 (7 mg): -1.4% HbA1c vs -0.1% placebo at 26 weeks.
14 mg
Month 3+ (optional escalation)
Higher efficacy dose. PIONEER-1 (14 mg): -1.9% HbA1c, -2.3 kg body weight vs placebo at 26 weeks.
How to Take Rybelsus Correctly (4 Steps)
Take on a completely empty stomach — first thing in the morning before any food, drink, or other oral medications
Swallow the tablet whole with no more than 120 mL (half a cup) of plain water only — no coffee, juice, or other liquids
Wait at least 30 minutes before eating, drinking anything other than water, or taking other oral medications
Log the dose in Shotlee immediately after taking it — including the time, any missed doses, and GI side effects if present
PIONEER-1 Clinical Trial Results (26 Weeks, Monotherapy)
HbA1c reduction (14 mg)
-1.9%
Mean HbA1c change from baseline vs -0.1% placebo in PIONEER-1 monotherapy trial.
Body weight change (14 mg)
-2.3 kg
Mean weight reduction at 26 weeks in PIONEER-1 vs -1.4 kg with 7 mg dose.
HbA1c target achieved
68.7%
Proportion of 14 mg patients achieving HbA1c < 7.0% at 26 weeks vs 31.3% placebo.
What to Track in Shotlee
Daily oral semaglutide requires consistent habits — use Shotlee to stay on track and measure your glycaemic progress.
Daily Dose Logs
Record each tablet taken, the time, and whether administration conditions were met (empty stomach, correct water volume).
Administration Timing
Log the time of dose and first meal to confirm your 30-minute fasting window is consistently maintained.
HbA1c & Glucose
Enter lab HbA1c results and fasting glucose readings at each clinic visit to track your glycaemic response over the dose escalation.
Weekly Weight
Track body weight weekly to monitor the modest but real weight reduction effect seen in PIONEER trials.
GI Side Effects
Log nausea, vomiting, and diarrhoea with severity and timing — GI events are most common in the first weeks of each dose escalation.
Missed Dose Tracking
Record any missed or improperly administered doses — irregular adherence is a key driver of suboptimal HbA1c outcomes.
Protocol FAQs
In PIONEER-1 (monotherapy, 26 weeks), Rybelsus 14 mg reduced HbA1c by 1.9% vs -0.1% with placebo. The 7 mg dose reduced HbA1c by 1.4%. These results are comparable to injectable GLP-1 agents for many patients.
Rybelsus is not approved for weight loss, but moderate weight reduction is seen in trials. PIONEER-1 showed -2.3 kg with 14 mg at 26 weeks. For obesity treatment, Wegovy (injectable semaglutide 2.4 mg) is the approved option.
Food significantly reduces semaglutide absorption through the oral route. Taking Rybelsus with food can reduce bioavailability by up to 50%. Always take on an empty stomach with no more than 120 mL water.
The 3 mg starting dose is for tolerability only. Meaningful HbA1c reduction typically begins with the 7 mg dose from week 5–8 onward, with full effect assessed at 3 months. Track your HbA1c at each clinic visit in Shotlee.
Both contain semaglutide, but the formulation and route differ. Ozempic is a once-weekly subcutaneous injection at 0.25–2 mg. Rybelsus is a once-daily oral tablet at 3–14 mg. Injectable semaglutide achieves higher bioavailability and stronger efficacy at equivalent doses.
Download Shotlee for free from the App Store, create your profile, and navigate to the dose logging screen. Select Rybelsus as your medication, then begin logging each dose with the exact amount, time, and injection site. Shotlee will automatically generate trend charts and adherence reports from your entries, giving you and your healthcare provider clear visibility into your protocol progress.
The highest-value metrics to track are: dose amount and timing for adherence monitoring, daily side effect type and severity for tolerability assessment, weekly fasting body weight under consistent conditions for efficacy tracking, waist circumference and body measurements for composition changes, lab results including metabolic panels and lipid profiles for safety monitoring, and daily appetite and energy ratings for subjective response assessment. Shotlee supports all of these in a single integrated dashboard.
Yes. Shotlee generates comprehensive reports from your tracking data that you can share with your healthcare provider during appointments. Having objective longitudinal data — rather than relying on memory — enables more efficient clinical consultations, more personalized dose adjustments, and better overall treatment outcomes. Many users find that sharing their Shotlee data significantly improves the quality of their provider interactions.
References
- [1]Clinical TrialAroda VR, et al. "PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes." Diabetes Care. 2019;42(9):1724-1732.
- [2]Clinical TrialHusain M, et al. "Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes." NEJM. 2019;381(9):841-851.
Track Your Rybelsus Protocol in Shotlee
Log daily doses with exact timing and fasting compliance, record HbA1c results and fasting glucose from every provider visit, track GI side effect severity over time, and monitor weekly body weight trends — all in one free app purpose-built for oral GLP-1 protocol management.
🚀 Use Shotlee for Free